Navigation Links
ESAs and a New Class of Late Stage Oral HIF-PH Inhibitors May Be Impacted by the Fact That Nephrologists Report Initiating ESAs at Lower Hemoglobins

EXTON, Pa., April 4, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, compared to just one year ago, the mean hemoglobin at erythropoiesis-stimulating agent (ESA) initiation has significantly declined and is nearing levels at which a blood transfusion may be required. In addition, nephrologists tend to overestimate the percent of stage 3 chronic kidney disease (CKD) patients on an ESA, but accurately assess the percent of patients being treated with an ESA in stage 4 and stage 5 non-dialysis. Amgen's Aranesp has a slightly higher share of late-stage CKD patients than do the other available ESAs, including Procrit (manufactured by Amgen and distributed by Janssen) and Amgen's Epogen.

(Logo: )

The ChartTrends®: Renal Anemia in CKD-ND 2012 (U.S.) report also covers the use of oral iron and IV iron in CKD-ND patients. AMAG Pharmaceutical's Feraheme, in number two share position behind Venofer, recently announced FDA acceptance of supplemental new drug application for label expansion to include iron deficiency anemia patients who cannot take oral iron. In addition, this study found that Feraheme patient share has declined directionally from 2011 with directional increases of the use of Sanofi's Ferrlecit."In this study, nearly half of physicians report initiating ESAs in CKD-ND at lower hemoglobin levels in the past year, something evident in the patient audit portion of this study as well," said BioTrends Research Group Director of Nephrology Rob Dubman . "This report could also have implications for the late-stage oral HIF-PH inhibitors in development, for example Akebia Therapeutics' AKB-6548 or FibroGen's/Astellas's FG-4592/ASP1517."

The BioTrends' TreatmentTrends: Nephrology (US) Q4 2012 report, found that over 20 percent of nephrologists expect to use AKB-6548 and FG-4592/ASP1517 products after ESA failures, respectively. Late stage oral HIF-PH inhibitors manufacturers must be considering when and how these agents will be used, especially when physicians are waiting longer to initiate ESAs.ChartTrends®: Renal Anemia in CKD-ND 2012 (U.S.) is a syndicated report series, in which 226 U.S. nephrologists provide patient chart data on 1,130 CKD-ND patients in the U.S. to uncover the actual management related to renal anemia. Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications, and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers.

TreatmentTrends®: Nephrology (U.S.) is a syndicated quarterly report series, based on primary market research that provides a comprehensive view of the current and expected future management of renal anemia and bone and mineral metabolism in patients with kidney disease. The Q1 2013 wave published in March 2013 and the Q2 2013 wave will publish in June with survey comments due April 10, 2013.

About BioTrends Research GroupBioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research GroupDecision Resources GroupRob Dubman

Christopher Comfort781-993-2592


SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
2. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
3. Medifast, Inc. Announces Favorable Resolution of Securities Class Action Lawsuit
4. Star Scientific Responds to Plaintiffs Purported Class Action Lawsuit
5. Class III Obese Patients Experience Adverse Events More Frequently Than the General Adverse Event Patient Population
6. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Affymax, Inc.
7. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
8. Ferring Pharmaceuticals Inc. Recognized for Best-in-Class Work-Life Portfolio
9. Nelson Laboratories to Host Free Educational Device Testing Classes at 2013 MD&M West Show
10. The law firms of Bernstein Litowitz Berger & Grossmann LLP and Labaton Sucharow LLP announce pendency of class action in In re Schering-Plough Corporation / ENHANCE Securities Litigation
11. Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
Post Your Comments:
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
Breaking Medicine News(10 mins):